Sampre Nutritions Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Enhanced Price Attractiveness

As of 9 June 2026, Sampre Nutritions Ltd trades at ₹10.95 per share, down 4.95% on the day from a previous close of ₹11.52. The stock’s 52-week high stands at ₹42.33, with a low of ₹5.76, indicating a wide trading range and significant volatility over the past year. The company’s micro-cap status and a Mojo Score of 37.0, graded as a Sell (upgraded from Strong Sell on 1 June 2026), reflect cautious market sentiment.

Crucially, the valuation grade has improved from fair to very attractive, driven primarily by a P/E ratio of 29.06 and a P/BV ratio of 0.97. The P/E ratio, while elevated relative to some peers, is tempered by the company’s low PEG ratio of 0.19, suggesting that earnings growth expectations are not fully priced in. The P/BV ratio below 1.0 indicates the stock is trading below its book value, a classic signal of undervaluation in equity markets.

Peer Comparison Highlights Relative Value

When compared with key FMCG peers, Sampre Nutritions’ valuation metrics stand out. For instance, SKM Egg Products, graded as Fair, trades at a P/E of 12.27 and EV/EBITDA of 7.68, while HMA Agro Industries, also rated Very Attractive, has a P/E of 7.13 and EV/EBITDA of 11.19. In contrast, Sampre’s EV/EBITDA ratio is 23.21, higher than these peers, reflecting either a premium for growth potential or operational inefficiencies.

Other FMCG companies such as Lotus Chocolate and Vadilal Enterprises trade at significantly higher P/E ratios of 84.85 and 81.23 respectively, with Vadilal also showing an EV/EBITDA of 24.17. This positions Sampre Nutritions as a more reasonably valued option within the sector, especially given its very attractive valuation grade.

Historical Performance Contextualises Valuation

Examining Sampre Nutritions’ returns relative to the Sensex reveals a mixed performance over various time horizons. The stock has underperformed the benchmark significantly in the short term, with a 1-week return of -18.53% versus Sensex’s -1.00%, and a 1-month return of -36.08% compared to -4.92% for the Sensex. Year-to-date, the stock has declined by 55.99%, far exceeding the Sensex’s 13.72% loss.

However, over longer periods, the picture is more nuanced. The stock delivered a robust 70.43% return over the past year, outperforming the Sensex’s -10.54%. Over five years, Sampre Nutritions has appreciated by 135.48%, significantly outpacing the Sensex’s 40.65% gain. Conversely, the 3-year and 10-year returns have lagged the benchmark, with -37.30% and -22.61% respectively, against Sensex gains of 16.99% and 172.10%.

This volatility and inconsistency in returns may explain the cautious Mojo Grade, despite the improved valuation metrics.

Operational Metrics and Financial Health

From an operational standpoint, Sampre Nutritions’ return on capital employed (ROCE) and return on equity (ROE) remain modest at 2.56% and 3.33% respectively. These low profitability ratios suggest limited efficiency in generating returns from capital and equity, which may weigh on investor confidence despite the attractive valuation.

The enterprise value to capital employed (EV/CE) ratio of 0.97 further supports the notion of undervaluation, indicating the market values the company at less than its capital base. However, the elevated EV to EBIT ratio of 37.96 signals that earnings before interest and tax are not keeping pace with enterprise value, a potential red flag for investors prioritising operational profitability.

Price Movements and Market Sentiment

The recent price decline of nearly 5% in a single day reflects ongoing market scepticism. The stock’s current price of ₹10.95 is substantially below its 52-week high, underscoring the significant correction it has undergone. This price action, combined with the micro-cap classification, suggests liquidity constraints and heightened volatility, factors that investors must weigh alongside valuation metrics.

Valuation Grade Upgrade: Implications for Investors

The upgrade from a fair to a very attractive valuation grade signals a shift in market perception, potentially driven by the stock’s low P/BV and PEG ratios. The PEG ratio of 0.19 is particularly noteworthy, implying that the stock’s price is low relative to its expected earnings growth, a classic indicator of undervaluation.

However, the Mojo Grade remains a Sell at 37.0, albeit improved from Strong Sell, reflecting ongoing concerns about the company’s fundamentals and market risks. Investors should consider this balanced view, recognising that while the stock may offer value on a price basis, operational challenges and market volatility remain significant.

Conclusion: Valuation Opportunity Amidst Operational Challenges

Sampre Nutritions Ltd’s recent valuation upgrade to very attractive, driven by a P/E of 29.06, P/BV below 1, and a low PEG ratio, presents a compelling case for value-oriented investors. The stock’s significant price correction and micro-cap status contribute to its risk profile, while modest profitability metrics temper enthusiasm.

Comparisons with FMCG peers reveal Sampre as reasonably priced, especially against highly valued companies like Lotus Chocolate and Vadilal Enterprises. However, investors should remain cautious given the company’s operational returns and recent price volatility.

In sum, Sampre Nutritions offers a potentially undervalued opportunity within the FMCG sector, but one that requires careful consideration of both valuation and fundamental factors before committing capital.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today